Rizatriptan orally-dissolving film - NAL Pharma

Drug Profile

Rizatriptan orally-dissolving film - NAL Pharma

Alternative Names: NAL-1606; Rizatriptan benzoate - NAL Pharma; Rizatriptan ODF

Latest Information Update: 28 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NAL Pharma
  • Class Antimigraines; Small molecules; Triazoles; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Migraine

Highest Development Phases

  • Clinical Phase Unknown Migraine

Most Recent Events

  • 28 Apr 2016 Chemical structure information added
  • 21 Apr 2016 Rizatriptan orally-dissolving film - NAL Pharma is available for licensing in World as of 21 Apr 2016. http://www.nalpharma.com/
  • 21 Apr 2016 Clinical trials in Migraine in Hong Kong (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top